Takahiro Nakayama

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Dietary fructose causes tubulointerstitial injury in the normal rat kidney

Takahiro Nakayama, Tomoki Kosugi, Michael Gersch et al. · American Journal of Physiology-Renal Physiology · 2010 · 175 citations

Medicine, Nephrology, Physiology +17

Effect of lowering uric acid on renal disease in the type 2 diabetic<i>db/db</i>mice

Tomoki Kosugi, Takahiro Nakayama, Marcelo Heinig et al. · American Journal of Physiology-Renal Physiology · 2009 · 173 citations · Full text

Medicine, Nephrology, Pharmacology +17